Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers

ABSTRACT Broadly neutralizing antibodies (bNAbs) have provided valuable insights into the humoral immune response to HIV-1. While rationally designed epitope scaffolds and well-folded gp140 trimers have been proposed as vaccine antigens, a comparative understanding of their antibody responses has not yet been established. In this study, we probed antibody responses to the N332 supersite and the membrane-proximal external region (MPER) in the context of heterologous protein scaffolds and native-like gp140 trimers. Ferritin nanoparticles and fragment crystallizable (Fc) regions were utilized as multivalent carriers to display scaffold antigens with grafted N332 and MPER epitopes, respectively. Trimeric scaffolds were also identified to stabilize the MPER-containing BG505 gp140.681 trimer in a native-like conformation. Following structural and antigenic evaluation, a subset of scaffold and trimer antigens was selected for immunization in BALB/c mice. Serum binding revealed distinct patterns of antibody responses to these two bNAb targets presented in different structural contexts. For example, the N332 nanoparticles elicited glycan epitope-specific antibody responses that could also recognize the native trimer, while a scaffolded BG505 gp140.681 trimer generated a stronger and more rapid antibody response to the trimer apex than its parent gp140.664 trimer. Furthermore, next-generation sequencing (NGS) of mouse splenic B cells revealed expansion of antibody lineages with long heavy-chain complementarity-determining region 3 (HCDR3) loops upon activation by MPER scaffolds, in contrast to the steady repertoires primed by N332 nanoparticles and a soluble gp140.664 trimer. These findings will facilitate the future development of a coherent vaccination strategy that combines both epitope-focused and trimer-based approaches. IMPORTANCE Both epitope-focused and trimer-based strategies are currently being explored in HIV-1 vaccine development, which aims to elicit broadly neutralizing antibodies (bNAbs) targeting conserved epitopes on the viral envelope (Env). However, little is known about the differences in antibody response to these bNAb targets presented by foreign scaffolds and native Env. In this study, a systematic effort was undertaken to design multivalent epitope scaffolds and soluble gp140.681 trimers with a complete antigenic surface, and to comparatively analyze the antibody responses elicited by these antigens to the N332 supersite and MPER in a mouse model. This study will inform both epitope-focused and trimer-based vaccine design and will facilitate integration of the two vaccine strategies. IMPORTANCE Both epitope-focused and trimer-based strategies are currently being explored in HIV-1 vaccine development, which aims to elicit broadly neutralizing antibodies (bNAbs) targeting conserved epitopes on the viral envelope (Env). However, little is known about the differences in antibody response to these bNAb targets presented by foreign scaffolds and native Env. In this study, a systematic effort was undertaken to design multivalent epitope scaffolds and soluble gp140.681 trimers with a complete antigenic surface, and to comparatively analyze the antibody responses elicited by these antigens to the N332 supersite and MPER in a mouse model. This study will inform both epitope-focused and trimer-based vaccine design and will facilitate integration of the two vaccine strategies.

[1]  Dong Soo Yun,et al.  HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies , 2016, Immunity.

[2]  C. Xiao,et al.  Regulation of B-cell development and tolerance by different members of the miR-17∼92 family microRNAs , 2016, Nature Communications.

[3]  D. Burton,et al.  Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability , 2016, Nature Communications.

[4]  D. Burton,et al.  Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles , 2016, Nature Communications.

[5]  R. Wyatt,et al.  High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.

[6]  Ben Murrell,et al.  Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. , 2016, Immunity.

[7]  Dennis R Burton,et al.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.

[8]  J. Mascola,et al.  Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. , 2016, Immunity.

[9]  A. Ward,et al.  Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer , 2016, Science.

[10]  R. Wyatt,et al.  Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers , 2015, Journal of Virology.

[11]  John P. Moore,et al.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.

[12]  Robyn L Stanfield,et al.  Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. , 2015, Immunity.

[13]  John P. Moore,et al.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity , 2015, Retrovirology.

[14]  John P. Moore,et al.  Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens , 2015, Proceedings of the National Academy of Sciences.

[15]  John P. Moore,et al.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.

[16]  I. Wilson,et al.  Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding , 2015, Scientific Reports.

[17]  J. Mascola.  The modern era of HIV-1 vaccine development , 2015, Science.

[18]  James B. Munro,et al.  Crystal structure, conformational fixation, and entry-related interactions of mature ligand-free HIV-1 Env , 2015, Nature Structural &Molecular Biology.

[19]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[20]  L. Morris,et al.  HIV broadly neutralizing antibody targets , 2015, Current opinion in HIV and AIDS.

[21]  R. Wyatt,et al.  Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.

[22]  Jiang Zhu,et al.  Computational tools for epitope vaccine design and evaluation. , 2015, Current opinion in virology.

[23]  U. Baxa,et al.  Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env , 2015, Journal of Virology.

[24]  John P. Moore,et al.  Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer , 2015, PLoS pathogens.

[25]  J. Dorfman,et al.  Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency , 2015, Journal of Virology.

[26]  John P. Moore,et al.  A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene , 2015, Journal of Virology.

[27]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[28]  B. Haynes,et al.  Polyreactivity and Autoreactivity among HIV-1 Antibodies , 2014, Journal of Virology.

[29]  Dennis R. Burton,et al.  Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding , 2014, Scientific Reports.

[30]  Tongqing Zhou,et al.  Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.

[31]  John P. Moore,et al.  Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies , 2014, Cell.

[32]  G. K. Hedestam,et al.  HIV-1 Env-Specific Memory and Germinal Center B Cells in C57BL/6 Mice , 2014, Viruses.

[33]  Cinque S. Soto,et al.  Transplanting Supersites of HIV-1 Vulnerability , 2014, PloS one.

[34]  John P. Moore,et al.  Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits , 2014, Retrovirology.

[35]  Wayne C Koff,et al.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.

[36]  James C Paulson,et al.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.

[37]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[38]  L. Stamatatos,et al.  Faculty Opinions recommendation of Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. , 2014 .

[39]  D. Burton,et al.  Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope , 2014, Journal of Virology.

[40]  John P. Moore,et al.  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[41]  J. Mascola,et al.  Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 , 2013, Journal of Virology.

[42]  Hanqin Peng,et al.  Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal Region of gp41 , 2013, Journal of Virology.

[43]  Yorgo Modis,et al.  Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. , 2013, Trends in biotechnology.

[44]  Tongqing Zhou,et al.  De novo identification of VRC01 class HIV-1–neutralizing antibodies by next-generation sequencing of B-cell transcripts , 2013, Proceedings of the National Academy of Sciences.

[45]  D. Irvine,et al.  Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry* , 2013, The Journal of Biological Chemistry.

[46]  D. Burton,et al.  Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 , 2013, The Journal of Immunology.

[47]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[48]  Maxim N. Artyomov,et al.  Deep Sequencing of the Murine Igh Repertoire Reveals Complex Regulation of Nonrandom V Gene Rearrangement Frequencies , 2013, The Journal of Immunology.

[49]  J. Mascola,et al.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.

[50]  Chaim A. Schramm,et al.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.

[51]  John P. Moore,et al.  Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein , 2013, Journal of Virology.

[52]  William R Schief,et al.  Advances in structure-based vaccine design. , 2013, Current opinion in virology.

[53]  Yan Liu,et al.  Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 , 2013, Nature Structural &Molecular Biology.

[54]  Ryan McBride,et al.  Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.

[55]  Baoshan Zhang,et al.  Mining the antibodyome for HIV-1–neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains , 2013, Proceedings of the National Academy of Sciences.

[56]  Keith E. J. Tyo,et al.  Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development , 2013, Current Opinion in Biotechnology.

[57]  S. Streatfield,et al.  Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development , 2012, Vaccine.

[58]  Michael S. Seaman,et al.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.

[59]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[60]  Adam Godzik,et al.  A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.

[61]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[62]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[63]  J. Mullikin,et al.  Somatic Populations of PGT135–137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics , 2012, Front. Microbio..

[64]  Thomas B Kepler,et al.  B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.

[65]  I. Wilson,et al.  Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. , 2011, Journal of molecular biology.

[66]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[67]  D. Baker,et al.  Computational Design of High-Affinity Epitope Scaffolds by Backbone Grafting of a Linear Epitope , 2011, Journal of Molecular Biology.

[68]  Po-Ssu Huang,et al.  Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold , 2011, Science.

[69]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[70]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[71]  J. Mullikin,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[72]  L. Stamatatos,et al.  Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. , 2011, Journal of molecular biology.

[73]  D. Baker,et al.  Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.

[74]  L. Stamatatos,et al.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.

[75]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[76]  D. Burton,et al.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.

[77]  T. Tiller,et al.  Cloning and expression of murine Ig genes from single B cells. , 2009, Journal of immunological methods.

[78]  Yih-En Andrew Ban,et al.  Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.

[79]  D. Burton,et al.  A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies , 2009, Journal of Virology.

[80]  E. Pai,et al.  Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. , 2008, Journal of molecular biology.

[81]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[82]  Jamie K. Scott,et al.  The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design , 2008, Microbiology and Molecular Biology Reviews.

[83]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[84]  Jamie K. Scott,et al.  The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design , 2008, Microbiology and Molecular Biology Reviews.

[85]  J. Sodroski,et al.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.

[86]  M. Fresno,et al.  Spleen B cells from BALB/c are more prone to activation than spleen B cells from C57BL/6 mice during a secondary immune response to cruzipain. , 2007, International immunology.

[87]  R. Wagner,et al.  Virus-like particles—universal molecular toolboxes , 2007, Current Opinion in Biotechnology.

[88]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[89]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[90]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[91]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[92]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[93]  J. Sodroski,et al.  Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.

[94]  J. Sodroski,et al.  Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.

[95]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[96]  M. Shlomchik,et al.  A Shannon entropy analysis of immunoglobulin and T cell receptor. , 1997, Molecular immunology.

[97]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[98]  F. McCutchan,et al.  Understanding the genetic diversity of HIV-1. , 2000, AIDS.